Open AccessChidamide-Induced Accumulation of Reactive Oxygen Species Increases Lenalidomide Sensitivity Against Multiple Myeloma Cells
Author(s) -
Duanfeng Jiang,
Kaixuan Zhang,
Yinghong Zhu,
Yan Zhu,
Lang Zou,
Jian Hu,
Yajuan Cui,
Wen Zhou,
Fangping Chen,
Yanjuan He
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s312249
Subject(s) - lenalidomide , reactive oxygen species , apoptosis , viability assay , multiple myeloma , chemistry , flow cytometry , cancer research , pharmacology , cell growth , microbiology and biotechnology , biology , immunology , biochemistry
Lenalidomide, an immunomodulatory drug (IMiD), is an effective therapy for the treatment of multiple myeloma (MM). However, prolonged treatment may be accompanied by toxicity, second primary malignancies, and drug resistance. There is an inherent vulnerability in MM cells that high rates of immunoglobulin synthesis resulting in the high level of reactive oxygen species (ROS). This provides a therapeutic potential for MM.